Wyss Institute launches RNA therapeutics startup EnPlusOne Biosciences Wyss Institute at Harvard University has partnered with Northpond Labs to launch EnPlusOne Biosciences. The startup aims to bring versatile, scalable RNA synthesis technology to market, with the goal of unlocking the development of new RNA drugs, vaccines, and gene-editing therapies.Read More
CRISPR edited rat embryos reveal cause of rare pediatric neurodegenerative disease Using CRISPR gene editing technology on rat embryos, University of Wisconsin-Madison researchers have revealed the mutation that is responsible for progressive gait abnormalities and other symptoms in human infants and young children with a rare neurodegenerative disease.Read More
Boosting TERRA levels damages DNA of hard-to-kill cancer cells: study Increasing levels of telomeric repeat-containing RNA (TERRA) damages the DNA of cancers with a particular form of replicative immortality and leads to cell death, according to Portuguese researchers who show that “anti-aging clocks” can be used to kill cancer cells.Read More
MIT team finds limitations of AlphaFold’s AI protein structures in drug discovery Advances in the modeling of protein-ligand interactions are needed to realize the potential of the artificial intelligence (AI) AlphaFold database of protein structure predictions in drug discovery, according to a new paper from researchers at the Massachusetts Institute of Technology (MIT).Read More